GoodRx has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer traction. New offerings have contributed to GDRX's recent positive developments, but the stock's rapid appreciation reflects these improvements. I remain marginally more positive, yet GDRX still presents considerable risk, warranting a continued neutral rating.
GoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call Transcript
GoodRx NASDAQ: GDRX reported second-quarter 2026 revenue of $200.4 million and adjusted EBITDA of $63.7 million, representing a 31.8% adjusted EBITDA margin, as growth in its Pharma Direct and subscription businesses offset pressure in prescription transaction revenue.
| Health Care Technology Industry | Healthcare Sector | Wendy Barnes CEO | XFRA Exchange | US38246G1085 ISIN |
| US Country | 697 Employees | - Last Dividend | - Last Split | 23 Sep 2020 IPO Date |
GoodRx Holdings, Inc. is an American healthcare company established in 2011, with its headquarters located in Santa Monica, California. It specializes in offering comprehensive information and tools designed to enable consumers in the United States to compare prices and save on prescription drug purchases. GoodRx operates by maintaining a sophisticated price comparison platform that not only provides consumers with accurate, geographically relevant prescription pricing information but also facilitates access to negotiated drug prices. Furthermore, the company caters to pharmacy benefit managers, who are instrumental in managing formularies and prescription transactions, including the determination of pricing between consumers and pharmacies.
GoodRx Holdings, Inc. provides a variety of healthcare products and services aimed at enhancing affordability and access to prescription medications and healthcare services: